Targeting the endocannabinoid system in Alzheimer's disease.
The endocannabinoid system is rapidly emerging as a potential drug target for a variety of immune-mediated central nervous system diseases. There is a growing body of evidence suggesting that endocannabinoid interventions may have particular relevance to Alzheimer's disease. Here we present a review of endocannabinoid physiology, the evidence that underscores its utility as a potential target for intervention in Alzheimer's disease, and suggest future pathways of research.
Koppel
Jeremy
J
The Albert Einstein College of Medicine and The Litwin-Zucker Research Center for the Study of Alzheimer's Disease and Memory Disorders, The Feinstein Institute for Medical Research, Manhasset, NY 11030, USA. jkoppel@lij.edu
Davies
Peter
P
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000276:immunology; D063385:Cannabinoid Receptor Modulators / Q000276:immunology / Q000502:physiology*; D003071:Cognition / Q000502:physiology; D063388:Endocannabinoids; D006801:Humans; D043882:Receptors, Cannabinoid / Q000187:drug effects / Q000276:immunology / Q000502:physiology*
D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D043882:Receptors, Cannabinoid